NCT06496165View on ClinicalTrials.gov

Remimazolam Besylate and Propofol Sedation on Hemodynamic for Coronary Artery Bypass Graft Patients

NANot yet recruitingINTERVENTIONAL
Enrollment

338

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Coronary Artery Disease
Interventions
DRUG

Remimazolam

Intravenous pump injection. The loading dose will be 0.1mg/kg, the maintenance dose will be 0.1-0.5mg/kg/h, with the target RASS be -2-0

DRUG

Propofol

Intravenous pump injection. The loading dose will be 0.5mg/kg, the maintenance dose will be 1-4mg/kg/h, with the target RASS be -2-0

Trial Locations (1)

200032

Zhongshan Hospital Fudan university, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER

NCT06496165 - Remimazolam Besylate and Propofol Sedation on Hemodynamic for Coronary Artery Bypass Graft Patients | Biotech Hunter | Biotech Hunter